New drug shrinks tumors in hard-to-treat lung and pancreatic cancers
Researchers presented trial results showing a safe drug shrinks tumors for lung and pancreatic cancer patients at a symposium in Spain.
Results from the AURORAS-1 Phase I trial show the anticancer drug ERAS-0015 is safe. The treatment helps tumors shrink in difficult cases involving one hundred and forty-eight patients. These findings come from data gathered during the study.
Dr Judy Wang explained that enrolled patients had tried other treatments before receiving this new therapy. The drug addresses mutations in the RAS gene which previously made designing effective treatments seem impossible.
Treatment caused a 44% response rate in pancreatic cancer patients with specific mutations. A response means patients experienced considerable tumor shrinkage which shows clinically meaningful activity from this new medical intervention.
ERAS-0015 acts as a molecular glue bringing proteins together to block signals from many cancer-driving RAS mutations found in patients. This method binds to the active RAS switch and stops the signals that lead to uncontrolled cancer growth.
“ERAS-0015 treatment caused a 44% response rate in patients with RAS-mutant pancreatic cancer and a 60% response rate in patients with RAS-mutant lung cancer.”

